Literature DB >> 25194786

Bipolar disorder and comorbidity: increased prevalence and increased relevance of comorbidity for hospital-based mortality during a 12.5-year observation period in general hospital admissions.

Dieter Schoepf1, Reinhard Heun2.   

Abstract

BACKGROUND: Bipolar disorder (BD) is associated with an increase of psychiatric and physical comorbidities, but the effects of these disorders on general hospital-based mortality are unclear. Consequently, we investigated whether the burden of comorbidity and its relevance on hospital-based mortality differed between individuals with and without BD during a 12.5-year observation period in general hospital admissions.
METHODS: During 1 January 2000 and 30 June 2012, 621 individuals with BD were admitted to three General Manchester Hospitals. All comorbidities with a prevalence ≥1% were compared with those of 6210 randomly selected and group-matched hospital controls of the same age and gender, regardless of priority of diagnoses. Comorbidities that increased the risk for hospital-based mortality (but not mortality outside of the hospitals) were identified using multivariate logistic regression analyses.
RESULTS: Individuals with BD had a more severe course of disease than controls that was associated with a higher total number of in-hospital deaths. Individuals with BD compared to controls had a substantial higher burden of comorbidities, the most frequent comorbidities included asthma, type-2 diabetes mellitus (T2DM), and alcohol dependence. 18 other diseases with a surplus of diabetes related complications were also increased. Fourteen comorbidities contributed to the prediction of hospital-based mortality in univariate analyses. Risk factors for hospital-based mortality in multivariate analyses were ischemic stroke, pneumonia, bronchitis, chronic obstructive pulmonary disease, T2DM, and hypertension. The impact of T2DM on hospital-based mortality was higher in individuals with BD than in controls. LIMITATIONS: The study design was not assigned to assess the type of BD, the current bipolar status, and if individuals with BD were treated with medication. It was neither possible to compare drug effects, nor to compare the adherence to treatment between samples.
CONCLUSION: In one of the largest samples of individuals with BD in general hospitals, the excess comorbity in individuals with BD compared to controls is in particular caused by asthma and T2DM. T2DM and its complications cause significant excess hospital-based mortality in individuals with BD.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Comorbidity; General hospitals; Mortality; Risk factors

Mesh:

Year:  2014        PMID: 25194786     DOI: 10.1016/j.jad.2014.08.025

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  16 in total

1.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

2.  Anxiety disorders and physical comorbidity: increased prevalence but reduced relevance of specific risk factors for hospital-based mortality during a 12.5-year observation period in general hospital admissions.

Authors:  Dieter Schoepf; Reinhard Heun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-12-04       Impact factor: 5.270

3.  Physical Comorbidities are Independently Associated with Higher Rates of Psychiatric Readmission in a Chinese Han Population.

Authors:  Chunyu Yang; Xiaomei Zhong; Huarong Zhou; Zhangying Wu; Min Zhang; Yuping Ning
Journal:  Neuropsychiatr Dis Treat       Date:  2020-09-10       Impact factor: 2.570

Review 4.  Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates.

Authors:  Vicent Balanzá-Martínez; Benedicto Crespo-Facorro; Ana González-Pinto; Eduard Vieta
Journal:  Front Physiol       Date:  2015-04-07       Impact factor: 4.566

Review 5.  Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications.

Authors:  Ellen F Charles; Christophe G Lambert; Berit Kerner
Journal:  Int J Bipolar Disord       Date:  2016-07-07

Review 6.  Psychiatric readmissions and their association with physical comorbidity: a systematic literature review.

Authors:  Lilijana Šprah; Mojca Zvezdana Dernovšek; Kristian Wahlbeck; Peija Haaramo
Journal:  BMC Psychiatry       Date:  2017-01-03       Impact factor: 3.630

7.  Quality of Life in Carotid Atherosclerosis: The Role of Co-morbid Mood Disorders.

Authors:  Maria Lecca; Luca Saba; Roberto Sanfilippo; Elisa Pintus; Michela Cadoni; Federica Sancassiani; Maria Francesca Moro; Davide Craboledda; Chiara Lo Giudice; Roberto Montisci
Journal:  Clin Pract Epidemiol Ment Health       Date:  2016-03-08

8.  Increased Subsequent Risk of Peptic Ulcer Diseases in Patients With Bipolar Disorders.

Authors:  Yi-Chao Hsu; Chih-Chao Hsu; Kuang-Hsi Chang; Chang-Yin Lee; Lee-Won Chong; Yu-Chiao Wang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

Review 9.  Significantly Higher Prevalence Rate of Asthma and Bipolar Disorder Co-Morbidity: A Meta-Analysis and Review Under PRISMA Guidelines.

Authors:  Ming-Kung Wu; Hung-Yu Wang; Yen-Wen Chen; Pao-Yen Lin; Ching-Kuan Wu; Ping-Tao Tseng
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate.

Authors:  Hui Hua Chang; Po See Chen; Yung Wen Cheng; Tzu-Yun Wang; Yen Kuang Yang; Ru-Band Lu
Journal:  Int J Neuropsychopharmacol       Date:  2018-04-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.